Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
NCT00770289
Last updated date
ABOUT THIS STUDY
Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's
response to treatment. The purpose of this study is the evaluation of the remission rates for
patients with MDD. The evaluation will involve the use of HAM-D 17, and HAM-D 7
questionnaires and the comparison of those questionnaires.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Outpatients
- 18-75 years old
- Patients diagnosed with MDD according to DSM IV without psychotic symptoms
- HAM-D17 > or = 18 on inclusion
- Patients receiving treatment for the first time or changing treatment based on their doctor's decision
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Subjects with potentially problematic compliance
- Subjects participating in an interventional trial within the last 3 months
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Major Depressive DisorderSertraline vs. Venlafaxine XR
NCT00179283
- Nashville, Tennessee
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderBrain Imaging Techniques That Predict Antidepressant Responsiveness
NCT00909155
- Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderA Study of MD-120 in Patients With Depression
NCT04345471
- Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Major Depressive DisorderNeurocognition and Work Productivity in Major Depressive Disorder (MDD)
NCT01468610
- Vancouver, British Columbia
ALL GENDERS
19 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD) | |||
| Official Title | Open Label, Observational, Non-interventional Study for the Evaluation of Remission Rates in Patients With MDD Under Treatment With Various Anti-depressives | |||
| Brief Summary | Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD. The evaluation will involve the use of HAM-D 17, and HAM-D 7 questionnaires and the comparison of those questionnaires. | |||
| Detailed Description | 12 weeks random | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Cohort | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Probability Sample | |||
| Study Population | Patients diagnosed with MDD who are either changing treatment or have never received treatment. | |||
| Condition | Major Depressive Disorder | |||
| Intervention | Other: Cohort
Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment). | |||
| Study Groups/Cohorts | Single group
Intervention: Other: Cohort | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 851 | |||
| Original Estimated Enrollment | 1000 | |||
| Actual Study Completion Date | December 2009 | |||
| Actual Primary Completion Date | December 2009 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years to 75 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Greece | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00770289 | |||
| Other Study ID Numbers | 0600B-102374 B2411003 ( Other Identifier: Pfizer ) | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | August 2012 | |||